“Safety of Tralokinumab in Pediatric Patients Aged 12-17 Years With Moderate to Severe Atopic Dermatitis: Results from the Phase 3 ECZTRA 6 Trial”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 2, Mar. 2023, p. s140, https://doi.org/10.25251/skin.7.supp.140.